NewAmsterdam Pharma Debuts As Publicly Traded Co. Focused On Developing Obicetrapib As A Potential Preferred Therapy For High Risk Cardiovascular Disease Patients
-- Business combination transaction with Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, completed on November 22, 2022 --
--